{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RAPP",
  "name": "Rapport Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/RAPP/",
  "json_url": "https://frontierpicks.com/dossiers/RAPP.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally. Price confirms the platform re-rate, but the next data binary (bipolar-mania Phase 2 topline) is Q4 2026, leaving a one-quarter void under a stock at its highs.",
  "invalidation_trigger": "A weekly close below $35 fails the June–July breakout above the prior $42.27 shelf and loses the rising 20-EMA. Secondary breaks: an 8-K disclosing a RAP-219 clinical hold or new SAE (single molecule, correlation ≈1 across all four indications), or bipolar-mania Phase 2 topline slipping out of Q4 2026 at the 2026-08-06 Q2 update.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-06",
  "invalidation_fired": false,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Pre-revenue clinical-stage: quarterly EPS 'misses' reflect trial spend, not demand. Q2 2026 R&D was $51.4M versus $22.7M a year earlier.",
    "Single-molecule platform. RAP-219 runs in focal onset seizures, bipolar mania, PGTCS and the long-acting injectable — one safety event impairs all four.",
    "Cash, equivalents and short-term investments of $436.1M at 2026-06-30, company-guided to fund planned operations into H2 2029 (2026-08-05 release).",
    "Tenacia Greater-China license: $20M upfront plus up to roughly $308M in milestones, non-dilutive.",
    "RAP-219 half-life revised up to ~22 days (disclosed 2026-04-21) — underwrites the long-acting injectable concept and implies slow washout if a safety signal emerges.",
    "Roughly 47.5M weighted-average shares in Q2 2026; single-desk flow has repeatedly moved the tape by mid-single-digit percentages intraday."
  ],
  "body_markdown": "\n_Reference close: $48.24 on 2026-08-21 (split/dividend-adjusted daily bars). All levels below are market levels, framed as analysis._\n\n## RAPP — Rapport Therapeutics, Inc.\n\n## Current Thesis\n\nThe July breakout has kept extending, and it is still being paid for with sell-side revisions rather than company data. RAPP closed $48.24 on 2026-08-21, 1.7% under the $49.07 52-week high, with RSI(14) at 75.9 and a three-month price change of +27.9%. The last week produced no company disclosure at all: BTIG reiterated Buy at an unchanged $65 on 2026-08-19, the third sell-side action inside a fortnight after HC Wainwright lifted its target from $40 to $66 on 2026-08-12 and BTIG published Buy/$65 alongside the 2026-08-05 Q2 print.\n\nWhat an investor is buying: one CNS molecule with a dated second efficacy readout — bipolar-mania Phase 2 topline, company-guided to **October 2026** in the 2026-08-05 business update — a Phase 3 already enrolling in the lead indication, and $436.1M in cash, equivalents and short-term investments at 2026-06-30 that the company says funds planned operations into the second half of 2029.\n\nWhat changed since the 2026-08-15 note is small but directional: the last analyst action was a reiteration at an unchanged number, not another raise, while price took out the prior high. The revision engine that drove June–August is now running against targets the stock has already closed most of the distance to.\n\n## Bull Case\n\n- **The second binary carries a month, not a quarter.** The 2026-08-05 release guided bipolar-mania Phase 2 topline to October 2026, tightened from Q4 2026, which had itself been pulled forward from H1 2027 with target enrollment increased and the statistical analysis plan modified so the trial can potentially serve as confirmatory evidence of effectiveness.\n- **A second Q4 datapoint sits behind it.** Initial open-label extension data in focal onset seizures guided to Q4 2026 (2026-08-05), firmed from the prior \"H2 2026\" language.\n- **Pivotal work is underway, not planned.** FOCUS 1 and FOCUS 2 were enrolling patients as of the 2026-08-05 update, following a Q2 2026 initiation that the company accelerated from Q3.\n- **Spend is tracking the trial count.** R&D of $51.4M in Q2 2026 against $22.7M a year earlier; G&A $9.4M against $6.8M. Inference, not a company statement: that step-up is consistent with two pivotals plus a Phase 2 running concurrently.\n- **Both Q4 readouts are funded on the company's own arithmetic.** $436.1M at 2026-06-30, guided into H2 2029 — through the October topline, the Q4 OLE data and the H1 2027 PGTCS Phase 3 start.\n- **The target ladder still sits above the tape.** HC Wainwright Buy/$66 on 2026-08-12; BTIG Buy/$65 reiterated 2026-08-05 and again 2026-08-19, after a $53 → $65 move earlier in the summer.\n- **Non-dilutive capital and pipeline depth behind RAP-219.** The Tenacia Greater-China license carried $20M upfront plus up to roughly $308M in milestones; RAP-219 long-acting injectable initial Phase 1 PK data is anticipated in 2027, with RAP-641 in IND-enabling work.\n\n## Bear Case\n\n- **No new efficacy data since 2026-04-21.** Every company disclosure since the 2026-05-07 Q1 update has been a timing or financial statement. A price set by upgrade cadence depends on the cadence continuing, and the 2026-08-19 action was a reiteration at an unchanged $65.\n- **Burn roughly doubled year-over-year.** Net loss $56.6M in Q2 2026 versus $26.7M in Q2 2025; first-half 2026 net loss of $76.47M with basic loss per share from continuing operations of $1.61 against $1.44. Cash went from $476.8M at 2026-03-31 to $436.1M at 2026-06-30.\n- **The loss line missed and was ignored.** Q2 EPS of $(1.19) against a $(0.96) consensus. That is trial spend, not demand, but it is the shape of the quarter the market chose not to price.\n- **Roughly six to nine weeks of calendar void into a single print.** As of 2026-08-23 there is no company-confirmed event before the October topline. Buyers within 1.7% of an all-time high are paying full price to wait.\n- **Correlation inside the pipeline is close to 1.** RAP-219 runs in focal onset seizures, bipolar mania, PGTCS and the long-acting injectable line. One safety event impairs all four. The ~22-day half-life disclosed 2026-04-21 that underwrites the LAI concept also implies slow washout if a signal emerges.\n- **Bipolar mania is a different endpoint in a different population.** Open-label epilepsy durability does not transfer statistically to a mania primary endpoint.\n\n## Setup & Price Structure\n\n**The narrative is maturing.** The narrative is well known to the desks that cover it and still working — but the marginal fuel has thinned. Dating that call: the re-rate began with BTIG's $53 → $65 in July and ran through HC Wainwright's $40 → $66 on 2026-08-12; the 2026-08-19 BTIG note held the same $65 rather than raising it. Price made a new high at $49.07 in the same window with no company headline behind it. That combination — price still advancing, target revisions flattening, no fresh disclosure — is a maturing leg, not an accelerating one. It is not saturated: coverage remains sell-side and specialist, with no evidence in the record of general-press or retail-forum clustering.\n\n**Structure.** The July move cleared the prior $42.27 all-time-high pivot; the $42–43 zone is the shelf that breakout created and the first structural reference underneath. Above it, the 2026-08-21 close of $48.24 sits 1.7% below the $49.07 high, so the stock is trading into resistance it set days earlier rather than into open air.\n\n**Crowding and positioning — observables, not a verdict:**\n- RSI(14) of 75.9 at the 2026-08-21 close, with price within 1.7% of the 52-week high and a three-month price change of +27.9%.\n- The two most recent live targets are $65 (BTIG, 2026-08-19) and $66 (HC Wainwright, 2026-08-12); the mid-July consensus target was $56.64 with 12 desks at Strong Buy. Price has since closed a large part of the distance to that consensus figure, which is now stale relative to the August raises.\n- No earnings inside the next 30 days: the Q1 print landed 2026-05-07 and Q2 on 2026-08-05, putting Q3 near 2026-11-05.\n- No filings in the recent window — no Form 4 insider sales, no shelf takedown or ATM disclosure observed while the stock trades near its high. That is an absence of evidence, and it can change on any business day.\n- Roughly 47.5M weighted-average shares in Q2 2026. Single-desk flow has repeatedly moved this tape by mid-single-digit percentages intraday, which cuts both ways around a readout.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-24 → 2026-09-22: nothing company-confirmed.** No scheduled data, no print, no announced conference appearance as of 2026-08-23. September healthcare-conference season is the only realistic source of an unscheduled headline, and no Rapport participation had been announced at the time of writing.\n- **~2026-10-31 (est.) — RAP-219 Phase 2 bipolar-mania topline.** Company-guided to October 2026 (2026-08-05). Outside the 30-day window, and the single event that resolves the current setup.\n- **Q4 2026 (company-guided) — initial open-label extension data, focal onset seizures.**\n- **~2026-11-05 (est.) — Q3 2026 financials and business update.** Estimated from the 2026-05-07 / 2026-08-05 cadence.\n- **H1 2027 (company-guided) — PGTCS Phase 3 initiation.**\n\n## What Would Change Our Mind\n\nThe structure that has to hold is the July breakout over the old $42.27 all-time-high pivot. Losing it would say the summer advance was a revision-driven overshoot that the October print was never going to be asked to justify: **a weekly close below $42** ends that read. On the fundamental side, three specific observations would break the frame independently of price:\n\n1. Any release or 8-K restating bipolar-mania topline timing as Q4 2026, year-end 2026 or 2027. The whole reason a buyer tolerates six-plus weeks of nothing is that the wait is bounded and dated.\n2. An 8-K disclosing a RAP-219 clinical hold, a new serious adverse event, or a protocol amendment adding safety monitoring in any RAP-219 trial — that single molecule carries focal seizures, bipolar mania, PGTCS and the LAI programme together.\n3. A shelf takedown or ATM disclosed into the high, or R&D stepping up again at the Q3 print without a reaffirmation of the H2 2029 runway.\n\nThe reverse case: an October primary-endpoint hit clean enough that the confirmatory-evidence framing survives into subsequent releases converts a re-rate built on analyst notes into one anchored to data, and the theme label moves back toward accelerating.\n\n## Correlation Notes\n\n- **Single-name concentration inside the pipeline.** Internal correlation across the four RAP-219 programmes is close to 1. This name does not diversify against itself.\n- **Sector beta.** As an unprofitable clinical-stage biotech with roughly 47.5M weighted-average shares, RAPP trades with small-cap biotech risk appetite (XBI-type flow) and with the rate path, since the value sits in cash flows dated 2029 and beyond. A broad biotech drawdown can take out the $42–43 shelf without any RAP-219 news.\n- **Read-across cohort.** Other CNS/epilepsy clinical-stage names — Xenon Pharmaceuticals among them — set the sentiment backdrop for AMPA/ion-channel programmes; Lundbeck's 2024 acquisition of Longboard Pharmaceuticals is the reference point desks use for what a positive epilepsy readout can be worth in M&A terms. Neither is a valuation input here, and neither would rescue a failed October topline.\n- **Catalyst clustering.** The October topline and the Q4 OLE data land inside the same quarter, so a single quarter carries two of the three remaining 2026 datapoints. Correlated timing means correlated repricing.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-23T16:27:52+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}